Answers are grounded in this paper and cite their sources.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy with dismal outcomes in relapsed/refractory settings, where nelarabine remains the sole approved agent with limited frontline efficacy. Genomic instability in T-ALL is sustained by a rewired DNA repair network, yet the functional reliance on DNA Ligase III (LIG3)-dependent alternative non-homologous end joining remains largely unexplored. By interrogating public transcriptomic cohorts, functional DepMap datasets, and siRNA-mediated knockdown, we evaluated LIG3 expression and essentiality in T-ALL. Pharmacological targeting was evaluated using Rhamnetin (RHM), a previously characterized LIG3-binding flavonoid, alone or combined with nelarabine across T-ALL cell lines and healthy peripheral blood mononuclear cells. LIG3 mRNA was uniformly expressed across T-ALL oncogenic subgroups. Functional assays confirmed LIG3 essentiality in T-ALL models. RHM dose-dependently reduced viability and clonogenic potential while sparing healthy cells. Mechanistically, RHM triggered a canonical DNA damage response with CHK1/CHK2 phosphorylation and γH2AX accumulation, driving CDC25A down-regulation, cell cycle perturbation, and apoptosis. Furthermore, RHM enhanced the anti-leukemic efficacy of nelarabine, displaying synergistic to additive interactions. These findings suggest LIG3 as an actionable dependency in T-ALL cells and support LIG3 inhibition, alone or combined with nelarabine, for therapeutic development.
No takes yet. Share an insight, caveat, or question.
Signorelli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: